AnaptysBio Inc ANAB

US Biotechnology

$51.00 ▼ -1.35% ($-0.70)

🔥 High Short Interest

Open $52.38

Prev Close $51.70

Day Range $50.80 – $52.38

52W Range $13.81 – $72.36

Market Cap $1.52B

Beta 0.82

EPS (TTM) $-0.88

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2017-01-26
Shares Out.	29,610,000
Website	anaptysbio.com/ ↗
Phone	13026587581
Employees	104
Revenue	$25.6M
Gross Profit	$25.6M
Net Income	-$52.9M
Free Cash Flow	$4.4M
Total Assets	$329.7M
Total Liabilities	$316.9M
Equity	$12.7M

About AnaptysBio Inc

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

AnaptysBio Inc is a publicly traded company under the ticker symbol ANAB on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.